In this episode, Dr. Cohen sits down with Dr. Mark Edney, Medical Director at Peninsula Institute for Laparoscopic and Robotic Surgery to discuss the limitations of relying on clinical pathology alone and how the addition of Prolaris allows providers to truly understand how a patient's tumor is behaving on a biological level. Dr, Edney also talks about his personal use of biomarkers in his practice and why he believes there is a slow adoption rate of molecular tests in the Urology space. Familial cancer screening and use of hereditary cancer testing to further personalize prostate cancer treatment is also discussed
Dr. Todd Cohen, VP of Medical Affairs at Myriad Genetics and Dr. Mark Edney, Medical Director at Peninsula Institute for Laparoscopic and Robotic Surgery discuss the evolution of prostate cancer treatment over the years.
Dr. Edney discusses the limitations of relying solely on clinical pathology for the treatment of localized prostate cancer, and how biomarker testing provides additional information to fully understand how a tumor is behaving on a molecular level. Dr. Edney also provides insight on his personal integration of biomarkers within his practice and why he believes molecular testing is slowly being adopted in the Urology space.